Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor

被引:37
作者
Zou, Ming-Xiang [1 ]
Lv, Guo-Hua [1 ]
Wang, Xiao-Bin [1 ]
Huang, Wei [2 ]
Li, Jing [1 ]
Jiang, Yi [3 ]
She, Xiao-Ling [3 ]
机构
[1] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, 139 Renminzhong Rd, Changsha 410011, Hunan, Peoples R China
[2] Cent S Univ, Inst Precis Med, Xiangya Hosp, Changsha, Hunan, Peoples R China
[3] Cent S Univ, Xiangya Hosp 2, Dept Pathol, Changsha, Hunan, Peoples R China
关键词
Spinal chordoma; Immunoscore; Tumor-infiltrating lymphocytes; PD-1; PD-L1; axis; Prognostic factor; Tumor immune microenvironment; Biomarker; TUMOR-INFILTRATING LYMPHOCYTES; PHASE-II; PD-L1; EXPRESSION; NEOANTIGEN LOAD; CANCER; ASSOCIATION; SURVIVAL; GROWTH; CELLS; RECURRENCE;
D O I
10.1093/neuros/nyy274
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND Currently, clinical implications of immune system cells in chordoma remain to be elucidated. OBJECTIVE To characterize in situ immune cell infiltrates, the Immunoscore, and investigate their correlation with clinicopathologic data of spinal chordoma patients and outcome. METHODS Tumor-infiltrating lymphocytes (TILs) subtypes were assessed in 54 tumor specimens using immunohistochemistry for CD3, CD4, CD8, CD20, Foxp3, PD-1, and PD-L1. RESULTS Overall, immune cell infiltrates were present in all samples and there was low or moderate correlation among several TILs subsets. PD-1(+) TILs density, CD3(+), and CD8(+) TILs densities in the tumor interior (TI) subarea were associated with surrounding muscle invasion by tumor, whereas PD-L1(+) TILs showed inverse association with tumor pathological grade and stage. The density of PD-1(+) TILs, PD-L1(+) TILs, CD4(+) TILs, and CD3(+) TILs both in the TI and combined tumor regions (TI and invasion margin) were significantly associated with local recurrence-free survival and overall survival (OS). However, Foxp3(+) TILs (P=.024) and CD8(+) TILs evaluated in the TI (P<.001) only correlated with OS. The Immunoscore predicted less aggressive clinical features and favorable outcomes. Patients with an Immunoscore of 4 had a median OS of 128 mo, while I0 (Immunoscore of 0) patients survived only 27 mo. Multivariate analysis demonstrated that the Immunoscore was an independent favorable prognostic factor of both local recurrence-free survival (P=.026) and OS (P=.046). CONCLUSION Our data suggest a clinically relevant role of the immune microenvironment in spinal chordoma and identify the Immunoscore as promising prognostic marker.
引用
收藏
页码:E318 / E333
页数:16
相关论文
共 65 条
  • [1] Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
    Anitei, Maria-Gabriela
    Zeitoun, Guy
    Mlecnik, Bernhard
    Marliot, Florence
    Haicheur, Nacilla
    Todosi, Ana-Maria
    Kirilovsky, Amos
    Lagorce, Christine
    Bindea, Gabriela
    Ferariu, Dan
    Danciu, Mihai
    Bruneval, Patrick
    Scripcariu, Viorel
    Chevallier, Jean-Marc
    Zinzindohoue, Franck
    Berger, Anne
    Galon, Jerome
    Pages, Franck
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1891 - 1899
  • [2] The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
    Ascierto, Paolo A.
    Capone, Mariaelena
    Urba, Walter J.
    Bifulco, Carlo B.
    Botti, Gerardo
    Lugli, Alessandro
    Marincola, Francesco M.
    Ciliberto, Gennaro
    Galon, Jerome
    Fox, Bernard A.
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [3] Chordoma: Natural history and results in 28 patients treated at a single institution
    Baratti, D
    Gronchi, A
    Pennacchioli, E
    Lozza, L
    Colecchia, M
    Fiore, A
    Santinami, M
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) : 291 - 296
  • [4] Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
    Bellmunt, J.
    Mullane, S. A.
    Werner, L.
    Fay, A. P.
    Callea, M.
    Leow, J. J.
    Taplin, M. E.
    Choueiri, T. K.
    Hodi, F. S.
    Freeman, G. J.
    Signoretti, S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 812 - 817
  • [5] Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO
  • [6] 2-1
  • [7] Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
    Berghoff, Anna S.
    Fuchs, Elisabeth
    Ricken, Gerda
    Mlecnik, Bernhard
    Bindea, Gabriela
    Spanberger, Thomas
    Hackl, Monika
    Widhalm, Georg
    Dieckmann, Karin
    Prayer, Daniela
    Bilocq, Amelie
    Heinzl, Harald
    Zielinski, Christoph
    Bartsch, Rupert
    Birner, Peter
    Galon, Jerome
    Preusser, Matthias
    [J]. ONCOIMMUNOLOGY, 2016, 5 (01):
  • [8] Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
    Berghoff, Anna Sophie
    Ricken, Gerda
    Wilhelm, Dorothee
    Rajky, Orsolya
    Widhalm, Georg
    Dieckmann, Karin
    Birner, Peter
    Bartsch, Rupert
    Preusser, Matthias
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (01) : 19 - 29
  • [9] Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review
    Bienkowski, Michal
    Preusser, Matthias
    [J]. CURRENT OPINION IN NEUROLOGY, 2015, 28 (06) : 647 - 658
  • [10] Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)
    Bompas, E.
    Le Cesne, A.
    Tresch-Bruneel, E.
    Lebellec, L.
    Laurence, V.
    Collard, O.
    Saada-Bouzid, E.
    Isambert, N.
    Blay, J. Y.
    Amela, E. Y.
    Salas, S.
    Chevreau, C.
    Bertucci, F.
    Italiano, A.
    Clisant, S.
    Penel, N.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (10) : 2168 - 2173